Evidence map›Paper›PMID 29892552›Full record

ArticleLeukemia research reports2018

Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature.

Daria Gaut, Joshua Sasine, Gary Schiller

Abstract readCase Reports
In one paragraph

Article in Leukemia research reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Frontiers in pharmacology · 2023
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daria GautDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, LA, California, USA.
Joshua SasineDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, LA, California, USA.
Gary SchillerDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, LA, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although rare, secondary clonal hematologic neoplasia may occur after successful therapy for acute promyelocytic leukemia (APL). These secondary clonal events may be considered therapy-related, but may also be due to an underlying background of clonal hematopoiesis from which both malignancies may develop. In this manuscript, we describe two patients with secondary clones after APL therapy characterized in one patient by deletion of chromosome 11q23 and, in the other, by monosomy of chromosome 7, and also provide a review of all secondary clonal disorders described after APL therapy. We suggest that since most reports identify karyotypic abnormalities not typically associated with chemotherapy, there may be another mechanism underlying secondary clonal development after complete response to initial APL therapy.

Indexed as

6-MP, 6-mercaptopurineAcute myelocytic leukemia (AML)AML, acute myelocytic leukemiaAPL, acute promyelocytic leukemiaATG, antithymyocyte globulinATO, arsenic trioxideATRA, all-trans retinoic acidCR, complete remissionFISH, fluorescence in situ hybridizationMDS, myelodysplastic syndromeMyelodysplastic syndrome (MDS)PML-RARalpha, promyelocytic leukemia/Retinoic acid receptor alphaSecondary clonet-AML, therapy-related acute myelocytic leukemiaTherapy-related acute myelocytic leukemia (t-AML)Therapy-related myelodysplastic syndrome (t-MDS)t- MDS, therapy-related myelodysplastic syndrome

Identifiers

PMID29892552
PMCPMC5993360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.